Thoracic Cancer · 2017 · 29 citations · 16 references
MedicineMolecular BiologyOncologyCancer GeneticsMolecular OncologyNeoplasiaGene Fusions In CancerLung CancerMalignant NeoplasmsMolecular Classification Of TumorsOncogene AmplificationOncogene MutationsLung AdenocarcinomaNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentOncogenic Receptor Tyrosine Kinase MutationsRos1 Fusion GenesRos1 InhibitorsRos1 OncogeneRos1-targeted Therapy
Lung adenocarcinomas with gene rearrangement in the receptor tyrosine kinase ROS1 have emerged as a rare molecular subtype. Although these lung adenocarcinomas respond to ROS1tyrosine kinase inhibitors, many patients ultimately acquire resistance. ROS1gene rearrangement is generally mutually exclusive with other driver genomic alterations, such as those in EGFR, KRAS, or ALK, thus multiple genomic alterations are extremely rare. Herein, we report a case of a 42-year-old man diagnosed with lung adenocarcinoma positive for a SDC4-ROS1 fusion, who was treated with crizotinib followed by three cycles of chemotherapy. A biopsy acquired after disease progression revealed the original SDC4-ROS1 fusion along with a KRAS point mutation (p.G12D).We reviewed the related literature to determine the frequency of gene mutations in non-small cell lung cancer patients. A better understanding of the molecular biology of non-small cell lung cancer with multiple driver genomic aberrations will assist in determining optimal treatment.
16
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Klarisa Rikova, Ailan Guo, Qingfu Zeng et al. · Cell · 2007 · 2.3K citations · Full text
Medicine, Cancer Biology, Oncology +16
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang et al. · New England Journal of Medicine · 2014 · 2K citations
Medicine, Oncology, Pharmacology +17
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou et al. · Journal of Clinical Oncology · 2012 · 1.6K citations · Full text
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi, Manabu Soda, Yuki Togashi et al. · Nature Medicine · 2012 · 1.3K citations
BRAF and RAS mutations in human lung cancer and melanoma.
Marcia S. Brose, Patrícia Volpe, Michael D. Feldman et al. · PubMed · 2002 · 1K citations